Abbott Laboratories (ABT), AbbVie Inc (ABBV) & More: Did You Know That This Stock Is Half What It Had Been?

3 High-Yield Pharma Stocks With Major CatalystsTechnically, Abbott Laboratories (NYSE:ABT) stock is trading at half of its 52-week high.

But only technically.

Abbott Laboratories (NYSE:ABT) stock hit a high in October of last year of 72.47, but when the new year hit, the company split in two, spinning its drug assets into AbbVie Inc (NYSE:ABBV). Investors that continued to hold AbbVie Inc (NYSE:ABBV) stock and Abbott Laboratories (NYSE:ABT) stock are looking at a combined value above $80 per share.

Much better.

Off the drugs
Without its drug division, first-quarter earnings required a little juggling to compare apples to apples. Diluted earnings per common share from continuing operations, excluding specified items — wow, that’s a mouthful — increased 5% compared to the same metric as the year-ago quarter. Basically, the company is pretending like it didn’t own AbbVie Inc (NYSE:ABBV) and then backing out special items from both quarters.

The nutrition business helped drive sales up 3.5% at constant currency. Sales of baby formula and the like were up 9% at constant currencies. Diagnostics were up 6.4% year over year, ignoring currency changes.

Dragging down sales were medical devices, which saw sales drop 3% at constant currency. Much of the decline came from sales of its drug-eluting stent and related products, which fell 15% in the U.S. compared to the first quarter of 2012. U.S. sales are being dragged down by pricing pressure as it competes with Boston Scientific Corporation (NYSE:BSX) and decreased usage by the doctors. Boston Scientific Corporation (NYSE:BSX) reported a similar experience with U.S. sales of drug-eluting stents down a whopping 33%.

Outside the U.S. sales of the segment actually increased 6.7% thanks to launches into new territories. It’s easy to see growth when the comparing quarter has zero sales. Boston Scientific Corporation (NYSE:BSX) wasn’t able to manage that, international sales were down 6.5%

You’ll recall that Johnson & Johnson (NYSE:JNJ) saw the writing on the walls and exited the drug-eluting stent business altogether. One has to wonder how long Abbott will give it. Abbott Laboratories (NYSE:ABT) stock might actually go up if the company followed Johnson & Johnson (NYSE:JNJ)’s lead.
I doubt we’ll see that happen, Abbott just got a new stent, Xience Xpedition, approved in January. Maybe the newest offering can turn things around.

Is Abbott Laboratories stock a buy?
I can see why Abbott Laboratories (NYSE:ABT) split off its drug business; the aforementioned growth in the combined stock price highlights the released value.

Of the two, though, I think AbbVie has greater potential for growth. It’s exposed to potential generic competition for its megablockbuster, Humira, but it has a nice pipeline to back it up.

Abbott Laboratories (NYSE:ABT) stock isn’t going to go anywhere until the company can get its medical device division moving back in the right direction. Unless you’re content with holding to collect the dividend, I’d recommend watching for the turnaround before investing.

The article Abbott Laboratories Stock Is Half What It Used to Be originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!